NL-OMON34696
Not yet recruiting
Phase 3
The Global randomized NBi bladder cancer study A Multi-Centre, International study to compare the use of Narrow Band Imaging (NBI) versus White light (WL) to assess recurrence of bladder cancer in terms of safety and efficacy. - NBI vs White light TURB
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients scheduled for treatment of a primary/recurrent NMIBC
- •Patients should be aged 18 years or older
- •No tumours in the upper urinary tract
- •No previous irradiation of the pelvis
Exclusion Criteria
- •Gross hematuria at the time of TURB. (Note: Gross hematuria is defined as a heavy bladder bleeding resulting in marked amounts of blood in the urine, which may interfere with cystoscopy).
- •Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.
- •\* Pregnant (all women of child\-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
First international Inter-Group Study for nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and AdolescentsEarly stage nodular lymphocyte predominant Hodgkin's lymphoma [nLPHL]MedDRA version: 14.0Level: PTClassification code 10029602Term: Non-Hodgkin's lymphoma stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2007-004092-19-GBMartin Luther University of Halle/Wittenberg250
Active, not recruiting
Phase 1
First international Inter-Group Study for nodular lymphocyte predominantHodgkin`s Lymphoma in Children and AdolescentsEUCTR2007-004092-19-FRMartin Luther University of Halle/Wittenberg200
Completed
Not Applicable
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutatio-C34 Malignant neoplasm of bronchus and lungMalignant neoplasm of bronchus and lungC34PER-115-09Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI),7
Active, not recruiting
Phase 1
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentEUCTR2014-004689-11-ROMorphoSys AG330
Active, not recruiting
Phase 1
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentEUCTR2014-004689-11-CZMorphoSys AG330